% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{LeCornet:275477,
      author       = {C. Le Cornet$^*$ and A. Y. Jung$^*$ and T. S. Johnson$^*$
                      and S. Behrens$^*$ and N. Obi and H. Becher and J.
                      Chang-Claude$^*$ and R. Turzanski-Fortner$^*$},
      title        = {{P}ostdiagnosis circulating osteoprotegerin and {TRAIL}
                      concentrations and survival and recurrence after a breast
                      cancer diagnosis: results from the {MARIE} patient cohort.},
      journal      = {Breast cancer research},
      volume       = {25},
      number       = {1},
      issn         = {1465-5411},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2023-00784},
      pages        = {42},
      year         = {2023},
      note         = {#EA:C020#LA:C020#},
      abstract     = {Experimental studies suggest a role for osteoprotegerin
                      (OPG) and tumor necrosis factor-related apoptosis-inducing
                      ligand (TRAIL) in mammary tumor development and progression.
                      These biomarkers have been minimally investigated with
                      respect to outcomes in breast cancer patients.OPG and TRAIL
                      were evaluated in blood samples collected from 2459 breast
                      cancer patients enrolled in the MARIE study, a prospective
                      population-based patient cohort, at median of 129 days after
                      diagnosis. Participants were between ages 50 and 74 at
                      diagnosis and recruited from 2002 to 2005 in two regions of
                      Germany. Follow-up for recurrence and mortality was
                      conducted through June 2015. Delayed-entry Cox proportional
                      hazards regression was used to assess associations between
                      OPG and TRAIL with all-cause and breast cancer-specific
                      mortality, and recurrence, both overall and by tumor hormone
                      receptor status.Median follow-up time was 11.7 years, with
                      485 deaths reported (277 breast cancer-specific). Higher OPG
                      concentrations were associated with a higher risk of
                      all-cause mortality (hazard ratio for 1-unit
                      log2-transformed concentration (HRlog2) = 1.24 $(95\%$
                      confidence interval 1.03-1.49). Associations were observed
                      in women diagnosed with ER-PR- tumors or discordant hormone
                      receptor status (ER-PR-, HRlog2 = 1.93 (1.20-3.10);
                      discordant ERPR, 1.70 (1.03-2.81)), but not for women with
                      ER + PR + tumors (HRlog2 = 1.06 (0.83-1.35)). OPG was
                      associated with a higher risk of recurrence among women with
                      ER-PR- disease (HRlog2 = 2.18 (1.39-3.40)). We observed no
                      associations between OPG and breast cancer-specific
                      survival, or for TRAIL and any outcome.Higher circulating
                      OPG may be a biomarker of a higher risk of poor outcome
                      among women diagnosed with ER- breast cancer. Further
                      mechanistic studies are warranted.},
      keywords     = {Humans / Female / Middle Aged / Aged / Breast Neoplasms:
                      pathology / Osteoprotegerin / Prospective Studies / Ligands
                      / TNF-Related Apoptosis-Inducing Ligand / Tumor Necrosis
                      Factor-alpha / Apoptosis / Biomarkers / Hormones / Breast
                      cancer survival (Other) / Estrogen receptor status (Other) /
                      OPG (Other) / TRAIL (Other) / Osteoprotegerin (NLM
                      Chemicals) / Ligands (NLM Chemicals) / TNF-Related
                      Apoptosis-Inducing Ligand (NLM Chemicals) / Tumor Necrosis
                      Factor-alpha (NLM Chemicals) / Biomarkers (NLM Chemicals) /
                      Hormones (NLM Chemicals)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37069615},
      pmc          = {pmc:PMC10108482},
      doi          = {10.1186/s13058-023-01625-4},
      url          = {https://inrepo02.dkfz.de/record/275477},
}